Response to treatment of chronic hepatitis C with interferon α in patients infected with HIV-1 is associated with higher CD4+ cell count
- Cite this article as:
- Mauss, S., Klinker, H., Ulmer, A. et al. Infection (1998) 26: 16. doi:10.1007/BF02768746
- 40 Downloads
The aim of this study was to assess the efficacy and tolerance of interferon α (IFN α) treatment of chronic hepatitis C in HIV-seropositive patients. Seventeen patients with actively replicating hepatitis C were consecutively enrolled and treated with IFN α 5 MIU three times a week and followed up for at least 6 months after cessation of treatment. Eight patients responded to IFN α therapy with a complete remission of signs of active hepatitis and viral replication (ALT, HCV-RNA) at the end of treatment with IFN α. A sustained complete remission (ALT, HCV-RNA) for at least 6 months after the end of treatment was achieved in five of these eight patients. Complete responders had higher CD4+ cell counts (median 525/μl) compared to non-responders (median 245/μl) (p<0.001). All patients but one completed at least 4 months of treatment. No severe toxicity (> WHO grade 2) due to IFN α treatment occurred. The results indicate that IFN α treatment of chronic hepatitis C in HIV-seropositive patients is successful in a considerable number of cases. Success of treatment with IFN α is related to higher CD4+ cell counts.